Benzinga | Jan 6, 2021 05:42AM EST

Alexandria Real Estate Equities Priced Upsized Public Offering of 6M Shares of Common Stock @$164/Share

Alexandria Real Estate Equities, Inc. ("Alexandria" or the "Company") (NYSE:ARE) announced Tuesday, the pricing of its upsized public offering of 6,000,000 shares of the Company's common stock at a price of $164.00 per share in connection with the forward sale agreements described below. The Company also granted the underwriters a 30-day option to purchase up to 900,000 additional shares. The offering is expected to close on or about January 8, 2021, subject to customary closing conditions.

J.P. Morgan, BofA Securities, Citigroup, Goldman Sachs & Co. LLC and RBC Capital Markets are acting as joint book-running managers for the offering. BTIG, Mizuho Securities, Scotiabank, SMBC Nikko, Barclays, BNP PARIBAS and Truist Securities are acting as book-running managers for the offering. Baird, Evercore ISI, JMP Securities LLC, BBVA, Capital One Securities, Fifth Third Securities, PNC Capital Markets LLC, Regions Securities LLC, TD Securities and Ramirez & Co., Inc. are acting as co-managers for the offering.

The Company has entered into forward sale agreements JPMorgan Chase Bank, N.A., Bank of America, N.A., Citibank, N.A., Goldman Sachs & Co. LLC and Royal Bank of Canada (the "forward purchasers") with respect to 6,000,000 shares of its common stock (and expects to enter into forward sale agreements with respect to an aggregate of 6,900,000 shares if the underwriters exercise their option to purchase additional shares in full). In connection with the forward sale agreements, the forward purchasers or their affiliates are expected to borrow and sell to the underwriters an aggregate of 6,000,000 shares of the common stock that will be delivered in this offering (or an aggregate of 6,900,000 shares if the underwriters exercise their option to purchase additional shares in full). Subject to its right to elect cash or net share settlement, which right is subject to certain conditions, the Company intends to deliver, upon physical settlement of such forward sale agreements on one or more dates specified by the Company occurring no later than July 5, 2022, an aggregate of 6,000,000 shares of its common stock (or an aggregate of 6,900,000 shares if the underwriters exercise their option to purchase additional shares in full) to the forward purchasers in exchange for cash proceeds per share equal to the applicable forward sale price, which will be the public offering price, less underwriting discounts and commissions, and will be subject to certain adjustments as provided in the forward sale agreements.

The Company will not initially receive any proceeds from the sale of shares of its common stock by the forward purchasers or their affiliates in the offering. The Company expects to use the net proceeds, if any, it receives upon the future settlement of the forward sale agreements to fund pending acquisitions, including 401 Park Drive, 201 Brookline Avenue and a related future development opportunity in the heart of the Company's Greater Boston life science cluster market, with remaining proceeds, if any, to be used for general working capital and other corporate purposes, which may include the reduction of the outstanding balance, if any, on the Company's unsecured senior line of credit, the outstanding balance, if any, and the outstanding indebtedness, if any, under the Company's commercial paper program. Selling common stock through the forward sale agreements enables the Company to set the price of such shares upon the pricing of the offering (subject to certain adjustments) while delaying the issuance of such shares and the receipt of the net proceeds by the Company until the expected funding is required.